Global Gene Therapy for Neurodegenerative Diseases Market Growth (Status and Outlook) 2026-2032
The global Gene Therapy for Neurodegenerative Diseases market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
United States market for Gene Therapy for Neurodegenerative Diseases is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Gene Therapy for Neurodegenerative Diseases is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Gene Therapy for Neurodegenerative Diseases is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Gene Therapy for Neurodegenerative Diseases players cover Voyager Therapeutics, Uniqure N.V., Axovant Gene Therapies, Novartis Ag, Amicus Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “Gene Therapy for Neurodegenerative Diseases Industry Forecast” looks at past sales and reviews total world Gene Therapy for Neurodegenerative Diseases sales in 2025, providing a comprehensive analysis by region and market sector of projected Gene Therapy for Neurodegenerative Diseases sales for 2026 through 2032. With Gene Therapy for Neurodegenerative Diseases sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy for Neurodegenerative Diseases industry.
This Insight Report provides a comprehensive analysis of the global Gene Therapy for Neurodegenerative Diseases landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Gene Therapy for Neurodegenerative Diseases portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy for Neurodegenerative Diseases market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy for Neurodegenerative Diseases and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy for Neurodegenerative Diseases.
This report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy for Neurodegenerative Diseases market by product type, application, key players and key regions and countries.
Segmentation by Type:
United States market for Gene Therapy for Neurodegenerative Diseases is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Gene Therapy for Neurodegenerative Diseases is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Gene Therapy for Neurodegenerative Diseases is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Gene Therapy for Neurodegenerative Diseases players cover Voyager Therapeutics, Uniqure N.V., Axovant Gene Therapies, Novartis Ag, Amicus Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “Gene Therapy for Neurodegenerative Diseases Industry Forecast” looks at past sales and reviews total world Gene Therapy for Neurodegenerative Diseases sales in 2025, providing a comprehensive analysis by region and market sector of projected Gene Therapy for Neurodegenerative Diseases sales for 2026 through 2032. With Gene Therapy for Neurodegenerative Diseases sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy for Neurodegenerative Diseases industry.
This Insight Report provides a comprehensive analysis of the global Gene Therapy for Neurodegenerative Diseases landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Gene Therapy for Neurodegenerative Diseases portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy for Neurodegenerative Diseases market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy for Neurodegenerative Diseases and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy for Neurodegenerative Diseases.
This report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy for Neurodegenerative Diseases market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Gene Replacement Therapy
- Gene Silencing Therapy
- Gene Editing Therapy
- Enzyme Replacement Therapy
- Hospitals and Clinics
- Research Institutions
- Biotechnology Companies
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Voyager Therapeutics
- Uniqure N.V.
- Axovant Gene Therapies
- Novartis Ag
- Amicus Therapeutics
- Regenxbio Inc.
- Sarepta Therapeutics
- Gensight Biologics
- Krystal Biotech
- Avexis
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Gene Therapy for Neurodegenerative Diseases Market Size (2021-2032)
2.1.2 Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Gene Therapy for Neurodegenerative Diseases by Country/Region (2021, 2025 & 2032)
2.2 Gene Therapy for Neurodegenerative Diseases Segment by Type
2.2.1 Gene Replacement Therapy
2.2.2 Gene Silencing Therapy
2.2.3 Gene Editing Therapy
2.2.4 Enzyme Replacement Therapy
2.2.5 Gene Therapy for Neurodegenerative Diseases Market Size by Type
2.2.5.1 Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.5.2 Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
2.3 Gene Therapy for Neurodegenerative Diseases Segment by Application
2.3.1 Hospitals and Clinics
2.3.2 Research Institutions
2.3.3 Biotechnology Companies
2.3.4 Others
2.3.5 Gene Therapy for Neurodegenerative Diseases Market Size by Application
2.3.5.1 Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.5.2 Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
3 GENE THERAPY FOR NEURODEGENERATIVE DISEASES MARKET SIZE BY PLAYER
3.1 Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Player
3.1.1 Global Gene Therapy for Neurodegenerative Diseases Revenue by Player (2021-2026)
3.1.2 Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Player (2021-2026)
3.2 Global Gene Therapy for Neurodegenerative Diseases Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 GENE THERAPY FOR NEURODEGENERATIVE DISEASES BY REGION
4.1 Gene Therapy for Neurodegenerative Diseases Market Size by Region (2021-2026)
4.2 Global Gene Therapy for Neurodegenerative Diseases Annual Revenue by Country/Region (2021-2026)
4.3 Americas Gene Therapy for Neurodegenerative Diseases Market Size Growth (2021-2026)
4.4 APAC Gene Therapy for Neurodegenerative Diseases Market Size Growth (2021-2026)
4.5 Europe Gene Therapy for Neurodegenerative Diseases Market Size Growth (2021-2026)
4.6 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Gene Therapy for Neurodegenerative Diseases Market Size by Country (2021-2026)
5.2 Americas Gene Therapy for Neurodegenerative Diseases Market Size by Type (2021-2026)
5.3 Americas Gene Therapy for Neurodegenerative Diseases Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Gene Therapy for Neurodegenerative Diseases Market Size by Region (2021-2026)
6.2 APAC Gene Therapy for Neurodegenerative Diseases Market Size by Type (2021-2026)
6.3 APAC Gene Therapy for Neurodegenerative Diseases Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2021-2026)
7.2 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Type (2021-2026)
7.3 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Gene Therapy for Neurodegenerative Diseases by Region (2021-2026)
8.2 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Type (2021-2026)
8.3 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL GENE THERAPY FOR NEURODEGENERATIVE DISEASES MARKET FORECAST
10.1 Global Gene Therapy for Neurodegenerative Diseases Forecast by Region (2027-2032)
10.1.1 Global Gene Therapy for Neurodegenerative Diseases Forecast by Region (2027-2032)
10.1.2 Americas Gene Therapy for Neurodegenerative Diseases Forecast
10.1.3 APAC Gene Therapy for Neurodegenerative Diseases Forecast
10.1.4 Europe Gene Therapy for Neurodegenerative Diseases Forecast
10.1.5 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Forecast
10.2 Americas Gene Therapy for Neurodegenerative Diseases Forecast by Country (2027-2032)
10.2.1 United States Market Gene Therapy for Neurodegenerative Diseases Forecast
10.2.2 Canada Market Gene Therapy for Neurodegenerative Diseases Forecast
10.2.3 Mexico Market Gene Therapy for Neurodegenerative Diseases Forecast
10.2.4 Brazil Market Gene Therapy for Neurodegenerative Diseases Forecast
10.3 APAC Gene Therapy for Neurodegenerative Diseases Forecast by Region (2027-2032)
10.3.1 China Gene Therapy for Neurodegenerative Diseases Market Forecast
10.3.2 Japan Market Gene Therapy for Neurodegenerative Diseases Forecast
10.3.3 Korea Market Gene Therapy for Neurodegenerative Diseases Forecast
10.3.4 Southeast Asia Market Gene Therapy for Neurodegenerative Diseases Forecast
10.3.5 India Market Gene Therapy for Neurodegenerative Diseases Forecast
10.3.6 Australia Market Gene Therapy for Neurodegenerative Diseases Forecast
10.4 Europe Gene Therapy for Neurodegenerative Diseases Forecast by Country (2027-2032)
10.4.1 Germany Market Gene Therapy for Neurodegenerative Diseases Forecast
10.4.2 France Market Gene Therapy for Neurodegenerative Diseases Forecast
10.4.3 UK Market Gene Therapy for Neurodegenerative Diseases Forecast
10.4.4 Italy Market Gene Therapy for Neurodegenerative Diseases Forecast
10.4.5 Russia Market Gene Therapy for Neurodegenerative Diseases Forecast
10.5 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Forecast by Region (2027-2032)
10.5.1 Egypt Market Gene Therapy for Neurodegenerative Diseases Forecast
10.5.2 South Africa Market Gene Therapy for Neurodegenerative Diseases Forecast
10.5.3 Israel Market Gene Therapy for Neurodegenerative Diseases Forecast
10.5.4 Turkey Market Gene Therapy for Neurodegenerative Diseases Forecast
10.6 Global Gene Therapy for Neurodegenerative Diseases Forecast by Type (2027-2032)
10.7 Global Gene Therapy for Neurodegenerative Diseases Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Gene Therapy for Neurodegenerative Diseases Forecast
11 KEY PLAYERS ANALYSIS
11.1 Voyager Therapeutics
11.1.1 Voyager Therapeutics Company Information
11.1.2 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
11.1.3 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Voyager Therapeutics Main Business Overview
11.1.5 Voyager Therapeutics Latest Developments
11.2 Uniqure N.V.
11.2.1 Uniqure N.V. Company Information
11.2.2 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product Offered
11.2.3 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Uniqure N.V. Main Business Overview
11.2.5 Uniqure N.V. Latest Developments
11.3 Axovant Gene Therapies
11.3.1 Axovant Gene Therapies Company Information
11.3.2 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product Offered
11.3.3 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Axovant Gene Therapies Main Business Overview
11.3.5 Axovant Gene Therapies Latest Developments
11.4 Novartis Ag
11.4.1 Novartis Ag Company Information
11.4.2 Novartis Ag Gene Therapy for Neurodegenerative Diseases Product Offered
11.4.3 Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Novartis Ag Main Business Overview
11.4.5 Novartis Ag Latest Developments
11.5 Amicus Therapeutics
11.5.1 Amicus Therapeutics Company Information
11.5.2 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
11.5.3 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Amicus Therapeutics Main Business Overview
11.5.5 Amicus Therapeutics Latest Developments
11.6 Regenxbio Inc.
11.6.1 Regenxbio Inc. Company Information
11.6.2 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product Offered
11.6.3 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Regenxbio Inc. Main Business Overview
11.6.5 Regenxbio Inc. Latest Developments
11.7 Sarepta Therapeutics
11.7.1 Sarepta Therapeutics Company Information
11.7.2 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
11.7.3 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Sarepta Therapeutics Main Business Overview
11.7.5 Sarepta Therapeutics Latest Developments
11.8 Gensight Biologics
11.8.1 Gensight Biologics Company Information
11.8.2 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product Offered
11.8.3 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Gensight Biologics Main Business Overview
11.8.5 Gensight Biologics Latest Developments
11.9 Krystal Biotech
11.9.1 Krystal Biotech Company Information
11.9.2 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product Offered
11.9.3 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Krystal Biotech Main Business Overview
11.9.5 Krystal Biotech Latest Developments
11.10 Avexis
11.10.1 Avexis Company Information
11.10.2 Avexis Gene Therapy for Neurodegenerative Diseases Product Offered
11.10.3 Avexis Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Avexis Main Business Overview
11.10.5 Avexis Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Gene Therapy for Neurodegenerative Diseases Market Size (2021-2032)
2.1.2 Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Gene Therapy for Neurodegenerative Diseases by Country/Region (2021, 2025 & 2032)
2.2 Gene Therapy for Neurodegenerative Diseases Segment by Type
2.2.1 Gene Replacement Therapy
2.2.2 Gene Silencing Therapy
2.2.3 Gene Editing Therapy
2.2.4 Enzyme Replacement Therapy
2.2.5 Gene Therapy for Neurodegenerative Diseases Market Size by Type
2.2.5.1 Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.5.2 Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
2.3 Gene Therapy for Neurodegenerative Diseases Segment by Application
2.3.1 Hospitals and Clinics
2.3.2 Research Institutions
2.3.3 Biotechnology Companies
2.3.4 Others
2.3.5 Gene Therapy for Neurodegenerative Diseases Market Size by Application
2.3.5.1 Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.5.2 Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
3 GENE THERAPY FOR NEURODEGENERATIVE DISEASES MARKET SIZE BY PLAYER
3.1 Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Player
3.1.1 Global Gene Therapy for Neurodegenerative Diseases Revenue by Player (2021-2026)
3.1.2 Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Player (2021-2026)
3.2 Global Gene Therapy for Neurodegenerative Diseases Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 GENE THERAPY FOR NEURODEGENERATIVE DISEASES BY REGION
4.1 Gene Therapy for Neurodegenerative Diseases Market Size by Region (2021-2026)
4.2 Global Gene Therapy for Neurodegenerative Diseases Annual Revenue by Country/Region (2021-2026)
4.3 Americas Gene Therapy for Neurodegenerative Diseases Market Size Growth (2021-2026)
4.4 APAC Gene Therapy for Neurodegenerative Diseases Market Size Growth (2021-2026)
4.5 Europe Gene Therapy for Neurodegenerative Diseases Market Size Growth (2021-2026)
4.6 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Gene Therapy for Neurodegenerative Diseases Market Size by Country (2021-2026)
5.2 Americas Gene Therapy for Neurodegenerative Diseases Market Size by Type (2021-2026)
5.3 Americas Gene Therapy for Neurodegenerative Diseases Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Gene Therapy for Neurodegenerative Diseases Market Size by Region (2021-2026)
6.2 APAC Gene Therapy for Neurodegenerative Diseases Market Size by Type (2021-2026)
6.3 APAC Gene Therapy for Neurodegenerative Diseases Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2021-2026)
7.2 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Type (2021-2026)
7.3 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Gene Therapy for Neurodegenerative Diseases by Region (2021-2026)
8.2 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Type (2021-2026)
8.3 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL GENE THERAPY FOR NEURODEGENERATIVE DISEASES MARKET FORECAST
10.1 Global Gene Therapy for Neurodegenerative Diseases Forecast by Region (2027-2032)
10.1.1 Global Gene Therapy for Neurodegenerative Diseases Forecast by Region (2027-2032)
10.1.2 Americas Gene Therapy for Neurodegenerative Diseases Forecast
10.1.3 APAC Gene Therapy for Neurodegenerative Diseases Forecast
10.1.4 Europe Gene Therapy for Neurodegenerative Diseases Forecast
10.1.5 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Forecast
10.2 Americas Gene Therapy for Neurodegenerative Diseases Forecast by Country (2027-2032)
10.2.1 United States Market Gene Therapy for Neurodegenerative Diseases Forecast
10.2.2 Canada Market Gene Therapy for Neurodegenerative Diseases Forecast
10.2.3 Mexico Market Gene Therapy for Neurodegenerative Diseases Forecast
10.2.4 Brazil Market Gene Therapy for Neurodegenerative Diseases Forecast
10.3 APAC Gene Therapy for Neurodegenerative Diseases Forecast by Region (2027-2032)
10.3.1 China Gene Therapy for Neurodegenerative Diseases Market Forecast
10.3.2 Japan Market Gene Therapy for Neurodegenerative Diseases Forecast
10.3.3 Korea Market Gene Therapy for Neurodegenerative Diseases Forecast
10.3.4 Southeast Asia Market Gene Therapy for Neurodegenerative Diseases Forecast
10.3.5 India Market Gene Therapy for Neurodegenerative Diseases Forecast
10.3.6 Australia Market Gene Therapy for Neurodegenerative Diseases Forecast
10.4 Europe Gene Therapy for Neurodegenerative Diseases Forecast by Country (2027-2032)
10.4.1 Germany Market Gene Therapy for Neurodegenerative Diseases Forecast
10.4.2 France Market Gene Therapy for Neurodegenerative Diseases Forecast
10.4.3 UK Market Gene Therapy for Neurodegenerative Diseases Forecast
10.4.4 Italy Market Gene Therapy for Neurodegenerative Diseases Forecast
10.4.5 Russia Market Gene Therapy for Neurodegenerative Diseases Forecast
10.5 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Forecast by Region (2027-2032)
10.5.1 Egypt Market Gene Therapy for Neurodegenerative Diseases Forecast
10.5.2 South Africa Market Gene Therapy for Neurodegenerative Diseases Forecast
10.5.3 Israel Market Gene Therapy for Neurodegenerative Diseases Forecast
10.5.4 Turkey Market Gene Therapy for Neurodegenerative Diseases Forecast
10.6 Global Gene Therapy for Neurodegenerative Diseases Forecast by Type (2027-2032)
10.7 Global Gene Therapy for Neurodegenerative Diseases Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Gene Therapy for Neurodegenerative Diseases Forecast
11 KEY PLAYERS ANALYSIS
11.1 Voyager Therapeutics
11.1.1 Voyager Therapeutics Company Information
11.1.2 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
11.1.3 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Voyager Therapeutics Main Business Overview
11.1.5 Voyager Therapeutics Latest Developments
11.2 Uniqure N.V.
11.2.1 Uniqure N.V. Company Information
11.2.2 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product Offered
11.2.3 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Uniqure N.V. Main Business Overview
11.2.5 Uniqure N.V. Latest Developments
11.3 Axovant Gene Therapies
11.3.1 Axovant Gene Therapies Company Information
11.3.2 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product Offered
11.3.3 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Axovant Gene Therapies Main Business Overview
11.3.5 Axovant Gene Therapies Latest Developments
11.4 Novartis Ag
11.4.1 Novartis Ag Company Information
11.4.2 Novartis Ag Gene Therapy for Neurodegenerative Diseases Product Offered
11.4.3 Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Novartis Ag Main Business Overview
11.4.5 Novartis Ag Latest Developments
11.5 Amicus Therapeutics
11.5.1 Amicus Therapeutics Company Information
11.5.2 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
11.5.3 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Amicus Therapeutics Main Business Overview
11.5.5 Amicus Therapeutics Latest Developments
11.6 Regenxbio Inc.
11.6.1 Regenxbio Inc. Company Information
11.6.2 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product Offered
11.6.3 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Regenxbio Inc. Main Business Overview
11.6.5 Regenxbio Inc. Latest Developments
11.7 Sarepta Therapeutics
11.7.1 Sarepta Therapeutics Company Information
11.7.2 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
11.7.3 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Sarepta Therapeutics Main Business Overview
11.7.5 Sarepta Therapeutics Latest Developments
11.8 Gensight Biologics
11.8.1 Gensight Biologics Company Information
11.8.2 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product Offered
11.8.3 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Gensight Biologics Main Business Overview
11.8.5 Gensight Biologics Latest Developments
11.9 Krystal Biotech
11.9.1 Krystal Biotech Company Information
11.9.2 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product Offered
11.9.3 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Krystal Biotech Main Business Overview
11.9.5 Krystal Biotech Latest Developments
11.10 Avexis
11.10.1 Avexis Company Information
11.10.2 Avexis Gene Therapy for Neurodegenerative Diseases Product Offered
11.10.3 Avexis Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Avexis Main Business Overview
11.10.5 Avexis Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Gene Therapy for Neurodegenerative Diseases Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Gene Replacement Therapy
Table 4. Major Players of Gene Silencing Therapy
Table 5. Major Players of Gene Editing Therapy
Table 6. Major Players of Enzyme Replacement Therapy
Table 7. Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 8. Global Gene Therapy for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 9. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Table 10. Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 11. Global Gene Therapy for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 12. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Table 13. Global Gene Therapy for Neurodegenerative Diseases Revenue by Player (2021-2026) & ($ millions)
Table 14. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Player (2021-2026)
Table 15. Gene Therapy for Neurodegenerative Diseases Key Players Head office and Products Offered
Table 16. Gene Therapy for Neurodegenerative Diseases Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Gene Therapy for Neurodegenerative Diseases Market Size by Region (2021-2026) & ($ millions)
Table 20. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region (2021-2026)
Table 21. Global Gene Therapy for Neurodegenerative Diseases Revenue by Country/Region (2021-2026) & ($ millions)
Table 22. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Country/Region (2021-2026)
Table 23. Americas Gene Therapy for Neurodegenerative Diseases Market Size by Country (2021-2026) & ($ millions)
Table 24. Americas Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Country (2021-2026)
Table 25. Americas Gene Therapy for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 26. Americas Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Table 27. Americas Gene Therapy for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 28. Americas Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Table 29. APAC Gene Therapy for Neurodegenerative Diseases Market Size by Region (2021-2026) & ($ millions)
Table 30. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region (2021-2026)
Table 31. APAC Gene Therapy for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 32. APAC Gene Therapy for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 33. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2021-2026) & ($ millions)
Table 34. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Country (2021-2026)
Table 35. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 36. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 37. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Region (2021-2026) & ($ millions)
Table 38. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 39. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Gene Therapy for Neurodegenerative Diseases
Table 41. Key Market Challenges & Risks of Gene Therapy for Neurodegenerative Diseases
Table 42. Key Industry Trends of Gene Therapy for Neurodegenerative Diseases
Table 43. Global Gene Therapy for Neurodegenerative Diseases Market Size Forecast by Region (2027-2032) & ($ millions)
Table 44. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share Forecast by Region (2027-2032)
Table 45. Global Gene Therapy for Neurodegenerative Diseases Market Size Forecast by Type (2027-2032) & ($ millions)
Table 46. Global Gene Therapy for Neurodegenerative Diseases Market Size Forecast by Application (2027-2032) & ($ millions)
Table 47. Voyager Therapeutics Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 48. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
Table 49. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 50. Voyager Therapeutics Main Business
Table 51. Voyager Therapeutics Latest Developments
Table 52. Uniqure N.V. Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 53. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product Offered
Table 54. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 55. Uniqure N.V. Main Business
Table 56. Uniqure N.V. Latest Developments
Table 57. Axovant Gene Therapies Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 58. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product Offered
Table 59. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Axovant Gene Therapies Main Business
Table 61. Axovant Gene Therapies Latest Developments
Table 62. Novartis Ag Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 63. Novartis Ag Gene Therapy for Neurodegenerative Diseases Product Offered
Table 64. Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. Novartis Ag Main Business
Table 66. Novartis Ag Latest Developments
Table 67. Amicus Therapeutics Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 68. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
Table 69. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Amicus Therapeutics Main Business
Table 71. Amicus Therapeutics Latest Developments
Table 72. Regenxbio Inc. Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 73. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product Offered
Table 74. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Regenxbio Inc. Main Business
Table 76. Regenxbio Inc. Latest Developments
Table 77. Sarepta Therapeutics Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 78. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
Table 79. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Sarepta Therapeutics Main Business
Table 81. Sarepta Therapeutics Latest Developments
Table 82. Gensight Biologics Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 83. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product Offered
Table 84. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Gensight Biologics Main Business
Table 86. Gensight Biologics Latest Developments
Table 87. Krystal Biotech Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 88. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product Offered
Table 89. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. Krystal Biotech Main Business
Table 91. Krystal Biotech Latest Developments
Table 92. Avexis Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 93. Avexis Gene Therapy for Neurodegenerative Diseases Product Offered
Table 94. Avexis Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Avexis Main Business
Table 96. Avexis Latest Developments
Table 1. Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Gene Therapy for Neurodegenerative Diseases Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Gene Replacement Therapy
Table 4. Major Players of Gene Silencing Therapy
Table 5. Major Players of Gene Editing Therapy
Table 6. Major Players of Enzyme Replacement Therapy
Table 7. Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 8. Global Gene Therapy for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 9. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Table 10. Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 11. Global Gene Therapy for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 12. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Table 13. Global Gene Therapy for Neurodegenerative Diseases Revenue by Player (2021-2026) & ($ millions)
Table 14. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Player (2021-2026)
Table 15. Gene Therapy for Neurodegenerative Diseases Key Players Head office and Products Offered
Table 16. Gene Therapy for Neurodegenerative Diseases Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Gene Therapy for Neurodegenerative Diseases Market Size by Region (2021-2026) & ($ millions)
Table 20. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region (2021-2026)
Table 21. Global Gene Therapy for Neurodegenerative Diseases Revenue by Country/Region (2021-2026) & ($ millions)
Table 22. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Country/Region (2021-2026)
Table 23. Americas Gene Therapy for Neurodegenerative Diseases Market Size by Country (2021-2026) & ($ millions)
Table 24. Americas Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Country (2021-2026)
Table 25. Americas Gene Therapy for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 26. Americas Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Table 27. Americas Gene Therapy for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 28. Americas Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Table 29. APAC Gene Therapy for Neurodegenerative Diseases Market Size by Region (2021-2026) & ($ millions)
Table 30. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region (2021-2026)
Table 31. APAC Gene Therapy for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 32. APAC Gene Therapy for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 33. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2021-2026) & ($ millions)
Table 34. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Country (2021-2026)
Table 35. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 36. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 37. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Region (2021-2026) & ($ millions)
Table 38. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 39. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Gene Therapy for Neurodegenerative Diseases
Table 41. Key Market Challenges & Risks of Gene Therapy for Neurodegenerative Diseases
Table 42. Key Industry Trends of Gene Therapy for Neurodegenerative Diseases
Table 43. Global Gene Therapy for Neurodegenerative Diseases Market Size Forecast by Region (2027-2032) & ($ millions)
Table 44. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share Forecast by Region (2027-2032)
Table 45. Global Gene Therapy for Neurodegenerative Diseases Market Size Forecast by Type (2027-2032) & ($ millions)
Table 46. Global Gene Therapy for Neurodegenerative Diseases Market Size Forecast by Application (2027-2032) & ($ millions)
Table 47. Voyager Therapeutics Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 48. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
Table 49. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 50. Voyager Therapeutics Main Business
Table 51. Voyager Therapeutics Latest Developments
Table 52. Uniqure N.V. Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 53. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product Offered
Table 54. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 55. Uniqure N.V. Main Business
Table 56. Uniqure N.V. Latest Developments
Table 57. Axovant Gene Therapies Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 58. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product Offered
Table 59. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Axovant Gene Therapies Main Business
Table 61. Axovant Gene Therapies Latest Developments
Table 62. Novartis Ag Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 63. Novartis Ag Gene Therapy for Neurodegenerative Diseases Product Offered
Table 64. Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. Novartis Ag Main Business
Table 66. Novartis Ag Latest Developments
Table 67. Amicus Therapeutics Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 68. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
Table 69. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Amicus Therapeutics Main Business
Table 71. Amicus Therapeutics Latest Developments
Table 72. Regenxbio Inc. Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 73. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product Offered
Table 74. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Regenxbio Inc. Main Business
Table 76. Regenxbio Inc. Latest Developments
Table 77. Sarepta Therapeutics Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 78. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
Table 79. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Sarepta Therapeutics Main Business
Table 81. Sarepta Therapeutics Latest Developments
Table 82. Gensight Biologics Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 83. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product Offered
Table 84. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Gensight Biologics Main Business
Table 86. Gensight Biologics Latest Developments
Table 87. Krystal Biotech Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 88. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product Offered
Table 89. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. Krystal Biotech Main Business
Table 91. Krystal Biotech Latest Developments
Table 92. Avexis Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 93. Avexis Gene Therapy for Neurodegenerative Diseases Product Offered
Table 94. Avexis Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Avexis Main Business
Table 96. Avexis Latest Developments
LIST OF FIGURES
Figure 1. Gene Therapy for Neurodegenerative Diseases Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Gene Therapy for Neurodegenerative Diseases Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Gene Therapy for Neurodegenerative Diseases Sales Market Share by Country/Region (2025)
Figure 8. Gene Therapy for Neurodegenerative Diseases Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type in 2025
Figure 10. Gene Therapy for Neurodegenerative Diseases in Hospitals and Clinics
Figure 11. Global Gene Therapy for Neurodegenerative Diseases Market: Hospitals and Clinics (2021-2026) & ($ millions)
Figure 12. Gene Therapy for Neurodegenerative Diseases in Research Institutions
Figure 13. Global Gene Therapy for Neurodegenerative Diseases Market: Research Institutions (2021-2026) & ($ millions)
Figure 14. Gene Therapy for Neurodegenerative Diseases in Biotechnology Companies
Figure 15. Global Gene Therapy for Neurodegenerative Diseases Market: Biotechnology Companies (2021-2026) & ($ millions)
Figure 16. Gene Therapy for Neurodegenerative Diseases in Others
Figure 17. Global Gene Therapy for Neurodegenerative Diseases Market: Others (2021-2026) & ($ millions)
Figure 18. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application in 2025
Figure 19. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Player in 2025
Figure 20. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region (2021-2026)
Figure 21. Americas Gene Therapy for Neurodegenerative Diseases Market Size 2021-2026 ($ millions)
Figure 22. APAC Gene Therapy for Neurodegenerative Diseases Market Size 2021-2026 ($ millions)
Figure 23. Europe Gene Therapy for Neurodegenerative Diseases Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size 2021-2026 ($ millions)
Figure 25. Americas Gene Therapy for Neurodegenerative Diseases Value Market Share by Country in 2025
Figure 26. United States Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region in 2025
Figure 31. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Figure 32. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Figure 33. China Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 37. India Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Country in 2025
Figure 40. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Figure 41. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Figure 42. Germany Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 43. France Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 56. APAC Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 57. Europe Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 59. United States Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 60. Canada Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 61. Mexico Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 62. Brazil Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 63. China Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 64. Japan Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 65. Korea Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 67. India Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 68. Australia Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 69. Germany Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 70. France Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 71. UK Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 72. Italy Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 73. Russia Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 74. Egypt Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 75. South Africa Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 76. Israel Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 77. Turkey Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 78. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 1. Gene Therapy for Neurodegenerative Diseases Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Gene Therapy for Neurodegenerative Diseases Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Gene Therapy for Neurodegenerative Diseases Sales Market Share by Country/Region (2025)
Figure 8. Gene Therapy for Neurodegenerative Diseases Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type in 2025
Figure 10. Gene Therapy for Neurodegenerative Diseases in Hospitals and Clinics
Figure 11. Global Gene Therapy for Neurodegenerative Diseases Market: Hospitals and Clinics (2021-2026) & ($ millions)
Figure 12. Gene Therapy for Neurodegenerative Diseases in Research Institutions
Figure 13. Global Gene Therapy for Neurodegenerative Diseases Market: Research Institutions (2021-2026) & ($ millions)
Figure 14. Gene Therapy for Neurodegenerative Diseases in Biotechnology Companies
Figure 15. Global Gene Therapy for Neurodegenerative Diseases Market: Biotechnology Companies (2021-2026) & ($ millions)
Figure 16. Gene Therapy for Neurodegenerative Diseases in Others
Figure 17. Global Gene Therapy for Neurodegenerative Diseases Market: Others (2021-2026) & ($ millions)
Figure 18. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application in 2025
Figure 19. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Player in 2025
Figure 20. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region (2021-2026)
Figure 21. Americas Gene Therapy for Neurodegenerative Diseases Market Size 2021-2026 ($ millions)
Figure 22. APAC Gene Therapy for Neurodegenerative Diseases Market Size 2021-2026 ($ millions)
Figure 23. Europe Gene Therapy for Neurodegenerative Diseases Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size 2021-2026 ($ millions)
Figure 25. Americas Gene Therapy for Neurodegenerative Diseases Value Market Share by Country in 2025
Figure 26. United States Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region in 2025
Figure 31. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Figure 32. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Figure 33. China Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 37. India Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Country in 2025
Figure 40. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Figure 41. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Figure 42. Germany Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 43. France Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Gene Therapy for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 56. APAC Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 57. Europe Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 59. United States Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 60. Canada Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 61. Mexico Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 62. Brazil Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 63. China Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 64. Japan Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 65. Korea Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 67. India Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 68. Australia Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 69. Germany Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 70. France Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 71. UK Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 72. Italy Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 73. Russia Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 74. Egypt Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 75. South Africa Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 76. Israel Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 77. Turkey Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 78. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Gene Therapy for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
